<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pretreatment local staging evaluation for rectal cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pretreatment local staging evaluation for rectal cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pretreatment local staging evaluation for rectal cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald Bleday, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Shibata, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael H Rosenthal, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Herbert Y Kressel, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Surgical resection is the cornerstone of curative therapy for patients with early stage, potentially resectable rectal cancer. The type of surgery depends on tumor stage and location within the rectum. Superficially invasive, small cancers may be effectively managed with limited surgery (such as local excision). However, most patients have more deeply invasive tumors that require low anterior resection or, in some cases, if located distally, abdominoperineal resection. Locally advanced tumors that are adherent or fixed to adjoining structures (eg, sacrum, pelvic sidewalls, prostate, or bladder) require more extensive surgery. (See  <a class="medical medical_review" href="/z/d/html/15311.html" rel="external">"Surgical treatment of rectal cancer"</a> and  <a class="medical medical_review" href="/z/d/html/2528.html" rel="external">"Treatment of locally recurrent rectal adenocarcinoma"</a>.)</p><p>The combination of adjuvant radiation therapy (RT) and chemotherapy can enhance local control and cure rates in patients with either transmural invasion (T3/T4) or regional lymph node involvement  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2529.html" rel="external">"Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy"</a>.)</p><p>Increasingly, such therapy is administered preoperatively. The more favorable long-term toxicity profile and better local control with preoperative as compared with postoperative long-course chemoradiotherapy for transmural or node-positive rectal cancer were shown in the seminal German Rectal Cancer Study Group trial. Subsequently, benefit has been shown for neoadjuvant short-course RT alone, although this approach is more popular outside of the United States. More recently, the concept of "total neoadjuvant therapy," in which both RT and adjuvant systemic chemotherapy are administered preoperatively, is gaining popularity for locally advanced tumors. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'German Rectal Cancer Study Group trial'</a> and  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Short-course radiotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Total neoadjuvant therapy for locally advanced tumors'</a>.)</p><p>Although there is not universal agreement, neoadjuvant approaches are generally considered for T3/T4 and/or clinically node-positive T1/T2 tumors  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>), distal rectal tumors (ie, tumors within 5 cm of the anal verge  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>)) for which preoperative chemoradiotherapy may enhance the ability to preserve the anal sphincter, and tumors that appear to invade or are in close proximity to the mesorectal fascia on preoperative imaging because of the decreased likelihood of achieving a tumor-free circumferential resection margin (CRM) with upfront surgery. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Indications for neoadjuvant treatment'</a>.)</p><p>The selection of appropriate patients for initial RT or chemoradiotherapy rather than surgery is heavily dependent on accurate preoperative locoregional staging of the depth of transmural penetration, the presence or absence of suspicious perirectal nodes, and the likely status of the CRM. Locoregional tumor staging is mainly accomplished through physical examination, endoscopy, computed tomography (CT) scans, magnetic resonance imaging, and transrectal endoscopic ultrasound (TEUS).</p><p>This topic review will cover the preoperative local staging evaluation of patients with rectal cancer. The clinical presentation, diagnosis, and staging evaluation of patients with newly diagnosed colorectal cancer; the surgical treatment of rectal cancer; neoadjuvant chemoradiotherapy and RT for rectal cancer; adjuvant therapy following resection for rectal cancer; management of locally advanced, unresectable rectal cancer; and recommendations for post-treatment surveillance are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15311.html" rel="external">"Surgical treatment of rectal cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2529.html" rel="external">"Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2528.html" rel="external">"Treatment of locally recurrent rectal adenocarcinoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2493.html" rel="external">"Post-treatment surveillance after colorectal cancer treatment"</a>.)</p><p></p><p class="headingAnchor" id="H624796"><span class="h1">SURGICAL ANATOMY</span><span class="headingEndMark"> — </span>Many surgical descriptions refer to the distance of a rectal cancer from the anal verge. The upper extent of the rectum is typically defined as 12 cm from the anal verge  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>). While the dentate line, the point at which the squamous mucosa of the anus transitions to the columnar mucosa of the rectum, is a more reliable landmark than the anal verge, it is not visible on cross-sectional imaging. As a result, the inferior and superior margins of the anal sphincter complex are typically used as imaging landmarks. (See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Surgical anatomy'</a>.)</p><p>If sphincter preservation is to be achieved, the tumor has to be located high enough above the top of the anorectal ring to allow for an adequate distal margin. This is more likely with midrectal and upper rectal tumors than with distal tumors, particularly those that impinge upon or invade the sphincter complex. Preoperative chemoradiotherapy may enhance the ability to perform sphincter preservation in some patients with low-lying tumors. However:</p><p class="bulletIndent1"><span class="glyph">●</span>High-quality definitive evidence is lacking that preoperative chemoradiotherapy can consistently convert patients who need abdominoperineal resection (APR) to where low anterior resection (LAR) is feasible. The German trial of preoperative versus postoperative chemoradiotherapy demonstrated that patients undergoing preoperative chemoradiotherapy were twice as likely to undergo a sphincter-sparing operation (39 versus 19 percent [<a href="#rid1">1</a>]); however, the absolute rates of APR in the two cohorts were not significantly different. (See  <a class="medical medical_review" href="/z/d/html/15311.html" rel="external">"Surgical treatment of rectal cancer", section on 'Low anterior resection'</a> and  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'T1-2N0 tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of preoperative chemoradiotherapy for very distal early stage rectal cancer (eg, T2N0) in an attempt to convert the operation from APR to LAR, or to proctectomy and coloanal anastomosis is used at some institutions, but it is controversial and not yet a widely accepted standard of care, unless the patient declines APR. Patients with a complete clinical response might also be considered appropriate candidates for a "watch and wait" protocol rather than immediate surgery. (See  <a class="medical medical_review" href="/z/d/html/106743.html" rel="external">"Overview of the management of rectal adenocarcinoma", section on 'Clinical T2N0 and cT1N0 not amenable to local excision'</a> and  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Nonoperative management (watch and wait)'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">HISTORY, PHYSICAL EXAMINATION, AND ENDOSCOPY</span><span class="headingEndMark"> — </span>Determining the best operative approach and the selection of appropriate patients for initial radiation therapy (RT) or chemoradiotherapy rather than surgery are heavily dependent on accurate preoperative assessment. Digital rectal examination (DRE), rigid sigmoidoscopy, and preoperative imaging studies assist in determining the need for radical resection versus local excision, and whether the patient is a candidate for preoperative therapy.</p><p>The initial history should include information on the status of rectal and urinary function, as well as the status of sexual function in males [<a href="#rid2">2</a>].</p><p>When present, specific symptoms may assist in localizing the tumor and predicting its local extent. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Tenesmus, the constant sensation of needing to move the bowels, usually indicates a large and possibly fixed tumor. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain with defecation suggests involvement of the lower third of the rectum; most cancers located above the sphincters are painless. Very painful cancers growing directly into the anal sphincter that affect the very sensitive anal mucosa are usually not amenable to sphincter-sparing surgery. (See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'Clinical presentation'</a>.)</p><p></p><p>DRE is mandatory in all patients. Fixation of the lesion to the anal sphincter, its relationship to the anorectal ring (the collection of muscles that makes up the sphincters  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>)), fixation to both the rectal wall and pelvic wall muscles (levators), and the status of the rectovaginal septum can be assessed.</p><p>Rigid proctoscopy is more accurate than flexible sigmoidoscopy to determine the distance between the distal tumor margin, the top of the anorectal ring, and the dentate line, as well as the orientation within the rectum (eg, anterior, posterior, left, and right) [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H8260590"><span class="h2">Complete colonoscopy</span><span class="headingEndMark"> — </span>Because of the incidence of synchronous second primary colorectal cancers (approximately 3 to 5 percent), all patients should undergo complete colonoscopy prior to surgical resection, whenever feasible. If malignant obstruction precludes a full colonoscopy (to the cecum) preoperatively, it should be performed within six months of definitive surgery, if possible. (See  <a class="medical medical_review" href="/z/d/html/2493.html" rel="external">"Post-treatment surveillance after colorectal cancer treatment", section on 'Perioperative colonoscopy'</a>.)</p><p>At the time of endoscopy, marking the distal end of the cancer with an India ink tattoo can allow identification of the original location of the tumor in a patient who has had a complete clinical response to neoadjuvant therapy, and it can also facilitate determination of the distal margin at the time of minimally invasive surgery.</p><p class="headingAnchor" id="H5"><span class="h1">IMAGING EVALUATION</span><span class="headingEndMark"> — </span>An algorithm outlining our approach to staging evaluation for individuals with newly diagnosed rectal cancer is provided, and described in detail in the sections below  (<a class="graphic graphic_algorithm graphicRef131308" href="/z/d/graphic/131308.html" rel="external">algorithm 1</a>).</p><p>For most patients with suspected rectal cancer, thin-cut magnetic resonance imaging (MRI) with 3 mm multiplanar T2-weighted imaging and with pelvic phased-array coil is the preferred imaging modality for evaluating the extent of the primary tumor as it will be able to provide information on the depth of transmural tumor invasion, the presence of suspicious regional nodes, the status of the circumferential resection margin (CRM), and invasion of other organs and structures. The Society of Abdominal Radiology has defined a series of MRI <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcdn.ymaws.com%2Fabdominalradiology.site-ym.com%2Fresource%2Fresmgr%2Feducation_dfp%2Frectal_cancer%2FMR_Protocols.pdf&amp;token=b4TrR%2BsZl3%2Bzbv5KAXJBcFRFDK%2Bw9JfIUzpEg9rAOm%2FBRG%2F9KPn2a6KIBU%2Bw5IxcdJ%2Fxh01AdiKHLgvA6gyxx1U6zWJQtCs6aPSF5cDkfIeTD374mwThZzvTelZjCVdKIl79liquh5zIvtnZvmc7Wg%3D%3D&amp;TOPIC_ID=2522" target="_blank">scanner-specific protocols</a> that are commonly used for this purpose.</p><p>Transrectal endoscopic ultrasound (TEUS) is an alternative, particularly for early stage (ie, T1-2N0) tumors, but for more advanced disease, it may be limited by the bulkiness of the tumor and the lack of depth to assess invasion of other organs. TEUS is particularly limited for posterior or posterolateral tumors in which the distance to the CRM cannot be estimated because the neighboring structures that allow assessment of the CRM are lacking.</p><p>This approach is in keeping with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid4">4</a>] and the European Society for Medical Oncology (ESMO) [<a href="#rid5">5</a>], which both state a preference for MRI over TEUS for pretreatment staging of rectal cancer, especially for intermediate and locoregionally advanced disease. Either TEUS or MRI is acceptable for a T1-2N0 tumor. </p><p>The information obtained with TEUS and MRI may be complementary, and in some cases, both procedures may be needed, particularly for mid-stage tumors where there is uncertainty about T2 versus T3N0 disease or T2N0 versus N1 status on either MRI or TEUS.</p><p>Regardless of the test that is chosen, the operating surgeon should ensure that the TEUS or MRI study is performed at an experienced center. A poor-quality MRI that is done in an inexperienced center without phased-array surface coils, without a 1.5- to 3T-field strength magnet, or without a rectal protocol can result in mismanagement because of errors in preoperative staging. The same is true for TEUS, which is highly dependent on operator experience.</p><p>Following the initial history and physical examination, digital rectal examination (DRE), rigid sigmoidoscopy, and colonoscopy, preoperative imaging studies assist in determining the optimal surgical approach and identifying patients who are candidates for preoperative radiation therapy (RT) or chemoradiotherapy. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Indications for neoadjuvant treatment'</a>.)</p><p>Rectal cancer imaging has become more critical for preoperative staging, since the order and types of treatment are often based upon pretreatment (clinical) stage as determined by imaging. Because the tumor (T) and nodal (N) categories used by the American Joint Committee on Cancer (AJCC) to assign clinical stage group were developed based upon postoperative pathology data rather than preoperative imaging findings  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>), the currently available imaging modalities are imperfect in delineating these stages and must be selected and interpreted with care. (See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'TNM staging system'</a>.)</p><p>The following sections will focus on the available locoregional staging modalities. The pretreatment clinical staging evaluation to evaluate for distant disease (ie, chest computed tomography [CT], liver MRI, positron emission tomography [PET]), and the role of serum tumor markers are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'Clinical staging evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'Tumor markers'</a>.)</p><p>There is debate over the utility of staging studies in early invasive cancers that are detected with a margin-negative polypectomy. Some adenomas with early invasive cancer (clinical T1 lesions) have a low (&lt;2 percent) risk of lymphatic metastasis [<a href="#rid6">6</a>], and consensus-based guidelines from the NCCN [<a href="#rid4">4</a>] suggest observation alone for single-specimen, completely resected pedunculated polyps with invasive cancer that have favorable histologic features and clear margins (pT1)  (<a class="graphic graphic_table graphicRef107550" href="/z/d/graphic/107550.html" rel="external">table 2</a>). Consensus-based guidelines from other expert groups recommend performing either high-resolution MRI or transrectal ultrasound (TRUS) to determine local T stage and assess for lymph node positivity for all patients with invasive rectal cancer, including those with pathologic T1 malignant polyps with favorable prognostic factors [<a href="#rid5">5,7,8</a>]. We agree with this approach. (See  <a class="medical medical_review" href="/z/d/html/2594.html" rel="external">"Overview of colon polyps", section on 'High-grade dysplasia or cancer'</a>.)</p><p class="headingAnchor" id="H2173749209"><span class="h2">Principles of rectal cancer staging by imaging</span></p><p class="headingAnchor" id="H4134108440"><span class="h3">T stage</span><span class="headingEndMark"> — </span>The T stage of a rectal cancer is determined by the depth of invasion of the primary tumor, including involvement of adjacent anatomic structures  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>). The layers of the rectum, beginning at the lumen, include the mucosa, muscularis mucosa, submucosa, muscularis propria, and subserosa/perirectal fat  (<a class="graphic graphic_figure graphicRef114851" href="/z/d/graphic/114851.html" rel="external">figure 2</a>). Portions of the mid and upper rectum are also covered by an external serosal layer of the peritoneum  (<a class="graphic graphic_figure graphicRef81248" href="/z/d/graphic/81248.html" rel="external">figure 3</a>). </p><p>Tis tumors are restricted to the mucosa, while T1 tumors have invaded the submucosa without involvement of the muscularis propria. T2 tumors  (<a class="graphic graphic_diagnosticimage graphicRef114585" href="/z/d/graphic/114585.html" rel="external">image 1</a>) invade but do not extend beyond the muscularis propria, while T3 tumors extend through the muscularis propria into the subserosa  (<a class="graphic graphic_diagnosticimage graphicRef115371" href="/z/d/graphic/115371.html" rel="external">image 2</a>) or perirectal fat  (<a class="graphic graphic_diagnosticimage graphicRef115373" href="/z/d/graphic/115373.html" rel="external">image 3</a>). T4a tumors invade a serosal equivalent layer (typically the peritoneum or mesorectal fascia), and T4b tumors invade another organ (eg, the pelvic floor muscles  (<a class="graphic graphic_diagnosticimage graphicRef115374" href="/z/d/graphic/115374.html" rel="external">image 4</a>), prostate, or vagina).</p><p class="headingAnchor" id="H1663806871"><span class="h4">cT1-2 tumors</span><span class="headingEndMark"> — </span>Patients with a T1-2 invasive rectal cancer arising in a polyp should all undergo local staging (either MRI or TRUS) to determine primary tumor stage and assess for lymph node positivity. Given the limited accuracy of MRI in this setting [<a href="#rid9">9,10</a>], some clinicians favor TRUS.</p><p class="headingAnchor" id="H421839589"><span class="h4">T2 versus T3 disease</span><span class="headingEndMark"> — </span>The distinction between a T2 tumor, which involves the muscularis propria, and a T3 tumor, which invades beyond the muscularis propria, is among the most important to be made in pretreatment staging because T2 tumors are typically managed initially by surgery, as long as they are clinically node negative, while T3 tumor stage may be an indication for preoperative RT or chemoradiotherapy, depending on tumor location and the degree of local invasion beyond the muscularis propria. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Indications for neoadjuvant treatment'</a>.)</p><p>This distinction can be very difficult. The presence of gross tumor in the perirectal fat immediately marks that tumor as T3, but the distinction between an advanced T2 tumor and a very early T3 tumor can be very small, sometimes as small as a single cell width, and may be well beyond the resolution of any current imaging modality. However, an important point is that a patient who is thought to have a T2N0 cancer on preoperative imaging who ends up with a pathologic early T3N0 tumor with &lt;2 mm of extramural invasion, good margins, and no poor prognostic histologic features can often be treated with observation rather than postoperative chemoradiotherapy, particularly if in the upper rectum. (See <a class="local">'T3 disease and the depth of extramural invasion'</a> below and  <a class="medical medical_review" href="/z/d/html/2529.html" rel="external">"Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy", section on 'T3N0 disease'</a>.)</p><p>Locally advanced rectal cancers can invade surrounding organs. The most common sites of invasion include the prostate, urethra, urinary sphincter complex, seminal vesicles, vagina, and osseous pelvis. These sites should be specifically assessed in the imaging evaluation of T stage.</p><p>MRI and TEUS offer the greatest value for the imaging evaluation of T stage in rectal cancer. The capabilities of each of these imaging modalities are further detailed in the sections that follow. (See <a class="local">'Magnetic resonance imaging'</a> below and <a class="local">'Transrectal endoscopic ultrasound'</a> below.)</p><p class="headingAnchor" id="H997077253"><span class="h4">T3 disease and the depth of extramural invasion</span><span class="headingEndMark"> — </span>Some have attempted to subdivide T3 disease according to the distance of tumor spread from the muscularis propria (ie, the depth of extramural invasion). While multiple thresholds have been proposed, one popular system uses four subdivisions of the T3 stage, as determined by thin-section MRI, as follows: T3a, &lt;1 mm; T3b, 1 to 5 mm; T3c, 6 to 15 mm; and T3d, &gt;15 mm [<a href="#rid11">11,12</a>]. In a number of studies, T3 tumors with &gt;5 mm of invasion beyond the muscularis propria (ie, T3c disease) had an inferior cancer-specific survival rate (approximately 54 percent, compared with 85 percent when the depth was 5 mm or less in one study) [<a href="#rid13">13-16</a>]. In addition, with increasing spread of tumor into the perirectal fat, there is increasing likelihood of nodal involvement and distant metastases at diagnosis [<a href="#rid17">17,18</a>]. These findings have led some to suggest that it is not necessarily the distinction between T2 and T3 tumors that will potentially govern treatment decisions but the identification of high-risk T3 tumors with a &gt;5 mm depth of extramural tumor invasion [<a href="#rid19">19</a>].</p><p>However, this is a controversial area at present, and there is not uniform agreement on whether decision making for neoadjuvant therapy should incorporate depth of extramural invasion. Updated guidelines for treatment of rectal cancer from the ESMO incorporate depth of extramural invasion beyond the muscularis propria as a factor in treatment allocation using the T3 subdivision system [<a href="#rid5">5</a>]. On the other hand, the AJCC has declined to adopt such a system, even in its most recent (2017, eighth edition) modification [<a href="#rid20">20</a>]. Furthermore, consensus-based guidelines from the NCCN [<a href="#rid4">4</a>] also do not stratify decision making for T3N0 disease according to depth of extramural invasion. At present, use of the terminology for subdividing T3 disease according to depth of extravascular invasion (T3a to T3d) is nonstandard in the United States. Thus, this issue remains unsettled. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Contribution of depth of extramural penetration'</a>.)</p><p class="headingAnchor" id="H2620631630"><span class="h4">T3 versus T4a disease</span><span class="headingEndMark"> — </span>The distinction between a clinical T3 and T4a tumor in the rectum requires careful assessment of the location of the peritoneal surfaces of the rectum relative to the site of tumor involvement. For rectal cancers below the level of the peritoneal reflection (typically at the level of the seminal vesicles or vaginal fornix), tumor within the mesorectal fat is evidence of T3 disease, and the tumor must extend to the mesorectal fascia to be considered a T4 lesion  (<a class="graphic graphic_figure graphicRef114851" href="/z/d/graphic/114851.html" rel="external">figure 2</a>). (See <a class="local">'Surgical anatomy'</a> above.)</p><p>By contrast, the anterior surface of the rectum is covered by serosa (peritoneum) at and above the peritoneal reflection. This coverage extends laterally around the rectum as we move superiorly toward the sigmoid colon  (<a class="graphic graphic_figure graphicRef81248" href="/z/d/graphic/81248.html" rel="external">figure 3</a>). This layer is generally not visible on imaging, so the location must be estimated based on local anatomy. In men, this reflection is typically located at the level of the seminal vesicles. In women, this is located near the posterior margin of the vagina. For tumors that extend above the peritoneal reflection, the presence of gross tumor in the pericolonic fat represents T4a disease if present in a serosally covered surface, and T3 disease if present in the uncovered surface.</p><p class="headingAnchor" id="H2991812508"><span class="h4">Upper rectal cancers</span><span class="headingEndMark"> — </span>For tumors that are located above the peritoneal reflection, it may be difficult to determine the true origin, and the term "rectosigmoid" cancer may be used. There may also be disagreement between the surgical location of the tumor, which generally relies on the linear distance from the anal verge as measured on rigid sigmoidoscopy or under tension at surgery, and the radiologic location (relative to the sacral promontory or peritoneal reflection), as assessed in nondistended, potentially folded bowel [<a href="#rid21">21</a>].</p><p>These issues may result in some confusion as to whether or not these tumors should be treated as colon or rectal cancers. The main distinction is the use of preoperative RT, which may be appropriate for transmural or node-positive rectal cancers but not primary colon cancers.</p><p>However, this distinction may not be clinically significant. The true rectum is a retroperitoneal structure that is located below the peritoneal reflection; the limitations of the bony pelvis make it difficult for the surgeon to achieve a wide soft tissue margin, and the higher rate of local recurrence that results can be mitigated through the use of RT, administered preoperatively or postoperatively. On the other hand, tumors in the upper rectum have a lower rate of local recurrence (&lt;10 percent) after total mesorectal excision compared with mid or distal tumors, and the benefit of RT appears to be much less [<a href="#rid22">22-25</a>]. At many institutions, adjuvant RT is not offered following surgery for such tumors unless there is T4 disease or multiple positive lymph nodes. (See  <a class="medical medical_review" href="/z/d/html/2529.html" rel="external">"Adjuvant therapy for resected rectal adenocarcinoma in patients not receiving neoadjuvant therapy", section on 'T3N0 disease'</a>.)</p><p class="headingAnchor" id="H3904926651"><span class="h4">Low rectal cancers</span><span class="headingEndMark"> — </span>Low rectal cancers can invade the sphincter complex. Because the muscularis propria of the rectum transitions into the internal anal sphincter  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>), there is no anatomic boundary between this layer of the rectum and the anus. The distance of the tumor from the upper margin of the sphincter complex is used as a reasonable estimate for the likelihood of internal sphincter involvement. Tumor that extends into the low mesorectal fat may also directly invade the external sphincter muscle and pelvic floor musculature; this should be specifically reported as it may alter the surgical management of these low tumors. (See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Intersphincteric resection for low rectal cancer'</a>.)</p><p class="headingAnchor" id="H434942567"><span class="h4">Rectal cancers arising in adenomas</span><span class="headingEndMark"> — </span>Rectal cancers that arise in adenomas present a special challenge for staging. Noninvasive imaging cannot reliably differentiate most invasive cancers from the adenomas in which they arise, so the extent of the adenoma-like mass may overestimate the actual area of invasive disease. Rectal MRI has been shown to commonly overstage cancers arising in rectal adenomas, with MRI T3 findings most commonly representing pathologic T2 or less disease [<a href="#rid26">26,27</a>]. In particular, the base of the adenoma's pedicle often shows irregularity of the muscularis propria layer and stranding in the mesorectal fat of the pedicle, which may be commonly mistaken for invasive disease. TEUS may add value in these cases, and discussion in a multidisciplinary tumor board is recommended.</p><p class="headingAnchor" id="H1993759929"><span class="h3">N stage</span><span class="headingEndMark"> — </span>The N stage of rectal cancer is determined by the number of regional lymph nodes that are involved by cancer and by the presence of isolated, non-nodal, perirectal tumor deposits  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>). The most recent (eighth edition) AJCC tumor, node, metastasis (TNM) staging classification defines N1a as involvement of one lymph node, N1b as involvement of two to three lymph nodes, and N1c as the presence of tumor deposits in the subserosa, mesentery, or mesorectal tissues without regional nodal involvement. N2a is defined as involvement of four to six lymph nodes, and N2b is defined as involvement of seven or more lymph nodes.</p><p>The regional lymph nodal stations for rectal cancer include those in the mesorectal and internal iliac drainage pathways  (<a class="graphic graphic_figure graphicRef114852" href="/z/d/graphic/114852.html" rel="external">figure 4</a>) [<a href="#rid28">28</a>]. According to the AJCC, the regional lymph nodes for rectal cancer include the mesorectal, superior rectal, inferior mesenteric, internal iliac (which includes the obturator nodes  (<a class="graphic graphic_figure graphicRef114850" href="/z/d/graphic/114850.html" rel="external">figure 5</a>)), and inferior rectal  (<a class="graphic graphic_table graphicRef51172" href="/z/d/graphic/51172.html" rel="external">table 3</a>). The internal iliac lymph nodes include the lateral sacral and presacral stations. The external iliac nodes are extraregional, and if involved, they are considered to represent stage IV disease  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'TNM staging system'</a>.)</p><p>The primary lymphatic drainage of the rectum extends from the mesorectal fat superiorly along the mesorectal vessels toward the origin of the inferior mesenteric artery. This is the primary path of lymphatic metastasis in the vast majority of rectal cancers [<a href="#rid29">29</a>]. Rectal cancers can spread laterally to the internal iliac distribution via blood vessels or lymphatics that traverse the mesorectal fascia  (<a class="graphic graphic_figure graphicRef114852" href="/z/d/graphic/114852.html" rel="external">figure 4</a>). The cancer cells need a conduit to pass through the mesorectal fascia, unless there is direct invasion. In one series of 448 patients, 322 of whom underwent lateral lymph node dissection, 13.8 percent had lateral (internal iliac) lymph node involvement [<a href="#rid30">30</a>].</p><p>While the internal iliac nodes are a less common site of lymph node involvement from rectal cancer than is mesorectal lymphadenopathy, these are the only regional lymph nodes for rectal cancer that are not routinely excised during standard mesorectal excision. One study showed that resection of lateral lymph nodes in the internal iliac compartment measuring at least 7 mm in short axis on the initial MRI resulted in a lower rate of lateral lymph node recurrence (8.7 versus 52.3 percent, hazard ratio 6.2, 95% CI 1.4-28.5) as compared with total mesorectal excision without a lateral lymph node dissection [<a href="#rid31">31</a>]. It is, therefore, crucial that abnormal nodes in this location be specifically recognized preoperatively so that an extended (lateral) lymphadenectomy can be considered. (See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Lateral pelvic lymph node dissection'</a>.)</p><p>Abnormal lymph nodes in the inguinal, external iliac, common iliac, and periaortic/paracaval nodal stations are considered extraregional and are scored as distant metastases in the AJCC TNM staging classification for rectal cancer. The distinction between regional and extraregional location can sometimes be difficult (eg, mesorectal versus iliac). Involvement of the inguinal lymph nodes should be carefully assessed whenever a low rectal cancer involves the anal sphincter since the lymphatic drainage for the sphincter flows through the inguinal stations  (<a class="graphic graphic_figure graphicRef114852" href="/z/d/graphic/114852.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Venous and lymphatic drainage'</a>.)</p><p class="headingAnchor" id="H779158683"><span class="h4">Radiographic characteristics of suspicious nodes</span><span class="headingEndMark"> — </span>The distinction between benign reactive nodes and nodes containing tumor is a diagnostic challenge [<a href="#rid32">32,33</a>]. In general, MRI is the modality that is most helpful for assessment of perirectal nodal involvement as it can identify involved nodes on the basis of characteristics other than size  (<a class="graphic graphic_diagnosticimage graphicRef115375" href="/z/d/graphic/115375.html" rel="external">image 5</a>) [<a href="#rid32">32,34-39</a>]. However, especially in the setting of early rectal cancer (cT1-2), the sensitivity of MRI in detecting nodal involvement is low (21 percent in one cohort study [<a href="#rid10">10</a>]). (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p>Most centers rely on a combination of size and morphology to determine whether a node is likely to be malignant or benign. There is considerable overlap in size between normal reactive nodes and those containing tumor, and this is especially problematic with small nodes. Between 15 and 42 percent of rectal cancers have small (&lt;5 mm) mesorectal lymph nodes containing tumor, resulting in poor diagnostic accuracy for all size-based criteria [<a href="#rid39">39</a>]. One decision analysis that weighted different size thresholds against the harms of treatment misallocation found that for perirectal lymph nodes, a cutoff of 8 mm or larger in the short axis offered the best tradeoff of benefits and harms among the possible size thresholds to call a node malignant based upon its size on pretreatment imaging [<a href="#rid40">40</a>].</p><p>The ability to detect a mixed intranodal signal and/or irregularity of the border may improve the sensitivity of MRI for detecting lymph node involvement [<a href="#rid35">35,41</a>]. Diffusion-weighted MRI sequences  (<a class="graphic graphic_diagnosticimage graphicRef115375" href="/z/d/graphic/115375.html" rel="external">image 5</a>) may also improve the specificity and accuracy of preoperative nodal staging [<a href="#rid42">42</a>]. In 2018, the Society of Abdominal Radiology recommended the adoption of node borders, signal heterogeneity, and shape for staging of lymph nodes in rectal cancer [<a href="#rid43">43</a>]. Under the new staging recommendations, lymph nodes are to be assessed based on short axis dimension and morphologic criteria, with positive nodes counted as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Any lymph node with short axis ≥9 mm</p><p class="bulletIndent1"><span class="glyph">●</span>Lymph nodes 5 to 8 mm in short axis with at least two morphologic criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Lymph nodes &lt;5 mm and all three morphologic criteria</p><p></p><p>Suspicious morphologic criteria include round shape, irregular borders, and heterogeneous signal intensity. An <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcdn.ymaws.com%2Fabdominalradiology.site-ym.com%2Fresource%2Fresmgr%2Feducation_dfp%2Frectal_cancer%2Fsar_primary_rectal_cancer_st.pdf&amp;token=qedg3%2FBQgYT21YnvwLlfO9LRktIez2Gt3Plvin6xIHj17qe5gZiA7qjEg%2FhuvCJyllg38PHJX7q%2FJddC8VQW7PT3zveYIDswQARhE5e94RqzphvjlQ0Wxb9kQLFSkSB9ZHjiuI1SKUuK2LNVbfqckg%3D%3D&amp;TOPIC_ID=2522" target="_blank">example staging template</a> is available based on these consensus guidelines. (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p>The ability to predict lymph node metastasis is particularly important for lymph nodes in the lateral compartment, which are not removed with routine total mesorectal excision. A persistently malignant-appearing lymph node in the lateral compartment despite neoadjuvant therapy may be an indication for extended lymphadenectomy, but the practice is not standardized and controversial. (See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Lateral pelvic lymph node dissection'</a>.)</p><p class="headingAnchor" id="H1999536959"><span class="h3">Circumferential resection margin</span><span class="headingEndMark"> — </span>The standard surgical technique for resection of a rectal cancer is total mesorectal excision, which entails removal of the entire mesorectum bounded by the mesorectal fascia. The outer boundary of this excision is known as the CRM (also called the lateral or radial margin). (See  <a class="medical medical_review" href="/z/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Radial margins'</a>.)</p><p>Patients who have tumor involvement of the CRM at the time of surgery have significantly higher rates of local recurrence, although most of the data were derived in the era before neoadjuvant therapy [<a href="#rid44">44</a>]. The MERCURY trial showed that extension of tumor to within 1 mm of the CRM on imaging was 92 percent accurate in predicting margin involvement at the time of surgery, and that patients with CRM involvement had worse disease-free and overall survival [<a href="#rid12">12,45,46</a>], a finding that has been confirmed by others [<a href="#rid17">17,44,47,48</a>]. As a result, tumors in close proximity (1 mm) to the CRM on imaging are referred to as having a "threatened" CRM. Because of the higher risk for locoregional recurrence, patients with an involved or threatened CRM are appropriate candidates for neoadjuvant chemoradiotherapy. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Mesorectal fascia involvement'</a>.)</p><p>As noted above, a number of studies have shown that T3 tumors with &gt;5 mm of invasion beyond the muscularis propria have inferior outcomes compared with those with lesser degrees of extramural invasion  (<a class="graphic graphic_diagnosticimage graphicRef115373" href="/z/d/graphic/115373.html" rel="external">image 3</a>). Thus, there are two major prognostic metrics related to radial tumor growth that can be determined by pretreatment local imaging: distance of growth beyond the muscularis propria and distance to the CRM. Although the T3 subdivision terminology is not used widely in the United States, we routinely report both distances, at least on rectal MRI studies. (See <a class="local">'T3 disease and the depth of extramural invasion'</a> above.)</p><p class="headingAnchor" id="H1688486174"><span class="h2">Individual staging modalities</span></p><p class="headingAnchor" id="H3682596629"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>A typical rectal cancer staging pelvic MRI study comprises multiplanar, thin-section (3 mm), T2-weighted images [<a href="#rid49">49</a>]. The use of intravenous contrast is controversial; while the addition of contrast did not improve tumor or nodal staging with MRI in three separate studies [<a href="#rid50">50-52</a>], other studies have shown that assessment of abnormal contrast enhancement patterns in lymph nodes can add diagnostic value [<a href="#rid41">41</a>].</p><p>Diffusion-weighted images and pre- and postcontrast T1-weighted images are also frequently acquired. While endorectal coil placement was previously required, modern phased-array external coils can now provide diagnostic image quality for most patients without the need for internal coil placement [<a href="#rid53">53-55</a>]. Imaging at a 3 Tesla field strength is generally preferred due to the improved tradeoff between spatial resolution, scan duration, and tissue contrast to noise ratio at higher field strength, although the impact on diagnostic performance is modest [<a href="#rid32">32,55,56</a>]. (See  <a class="medical medical_review" href="/z/d/html/5309.html" rel="external">"Principles of magnetic resonance imaging", section on 'MRI technology and pulse sequences'</a>.)</p><p>A strength of MRI includes superior soft tissue contrast compared with CT and ultrasound, which can be used to differentiate malignant tissue from the muscularis propria of the rectum and to define tumor infiltration of the mesorectal fascia. The images provide examples of T2-weighted MRI images for a T2 rectal tumor  (<a class="graphic graphic_diagnosticimage graphicRef114585" href="/z/d/graphic/114585.html" rel="external">image 1</a>), an "early" T3 rectal tumor  (<a class="graphic graphic_diagnosticimage graphicRef115371" href="/z/d/graphic/115371.html" rel="external">image 2</a>), a late T3 rectal tumor with more than 5 mm of invasion beyond the muscularis propria  (<a class="graphic graphic_diagnosticimage graphicRef115373" href="/z/d/graphic/115373.html" rel="external">image 3</a>), a T4b rectal tumor invading the pelvic floor musculature and perineal fat  (<a class="graphic graphic_diagnosticimage graphicRef115374" href="/z/d/graphic/115374.html" rel="external">image 4</a>), and a T4b tumor with invasion of the anterior CRM and formation of a rectovaginal fistula  (<a class="graphic graphic_diagnosticimage graphicRef117815" href="/z/d/graphic/117815.html" rel="external">image 6</a>).</p><p>MRI is capable of assessing all of the nodal stations of the pelvis and lower abdomen with a wider field of view than TEUS. In addition to size, MRI can demonstrate lymph node features, such as internal signal inhomogeneity, that can be predictive of tumor involvement [<a href="#rid35">35</a>]. Representative images of pathologic mesorectal  (<a class="graphic graphic_diagnosticimage graphicRef115375" href="/z/d/graphic/115375.html" rel="external">image 5</a>) and internal iliac lymph nodes  (<a class="graphic graphic_diagnosticimage graphicRef115377" href="/z/d/graphic/115377.html" rel="external">image 7</a>) are provided.</p><p>MRI also offers the ability to assess soft tissue features that are generally not accessible via other modalities. For example, MRI can demonstrate altered venous enhancement, which is characteristic of extramural vascular invasion [<a href="#rid57">57,58</a>]. Extramural vascular invasion is a negative prognostic factor. In one meta-analysis, MRI-detected extramural vascular invasion was associated with more frequent metastases both at diagnosis and during post-treatment follow-up [<a href="#rid59">59</a>]. Beyond its prognostic relevance, the finding of extramural vascular invasion does not alter the T stage, nor is it used to select patients for neoadjuvant RT or chemoradiotherapy. (See  <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">"Pathology and prognostic determinants of colorectal cancer", section on 'Lymphovascular invasion'</a>.)</p><p>Another advantage of MRI over TEUS is that it allows the study of stenotic tumors. The disadvantages of MRI include a spatial resolution that is limited to approximately 1 mm with current techniques, and cost.</p><p>The accuracy of preoperative surface phased-array coil MRI in predicting rectal cancer T stage and nodal status can be illustrated by the results of a compilation of data from seven (2009 or later) systematic reviews by the Agency for Healthcare Research and Quality (AHRQ) [<a href="#rid60">60</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For T stage (T3/T4 versus T1/T2  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>)), the sensitivity was 87 percent (95% CI 81-92 percent), and the specificity was 75 percent (95% CI 65-80 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For lymph node involvement (any involved versus all clear), the sensitivity was 77 percent (95% CI 69-84 percent), and the specificity was 71 percent (95% CI 59-81 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For status of the CRM (involved versus clear), the sensitivity was 77 percent (95% CI 57-90 percent), and the specificity was 94 percent (95% CI 88-97 percent).</p><p></p><p>However, there was notable heterogeneity among the studies in the criteria used to define "positive" cases, particularly in assessment of nodal status. Lymph node size ≥5 mm, irregular borders, and mixed signal intensity were used in different combinations across the studies to define "involved" nodes. Status of the CRM was also variably defined, ranging from direct contiguity of tumor with the mesorectal fascia to tumor extension ≤5 mm from the mesorectal fascia.</p><p>Others note limited accuracy of MRI for both T and N staging among patients with cT1-2 tumors [<a href="#rid9">9,10</a>]. (See <a class="local">'cT1-2 tumors'</a> above.)</p><p>Diffusion-weighted MRI uses the diffusion of water molecules to generate contrast in MRI images. Combining diffusion-weighted MRI with T2-weighted imaging improves identification of metastatic lymph nodes in the pelvis  (<a class="graphic graphic_diagnosticimage graphicRef115376" href="/z/d/graphic/115376.html" rel="external">image 8</a>). However, both sensitivity (67 to 78 percent) and specificity (60 to 67 percent) are low to moderate, and the diagnostic accuracy is only approximately 70 percent [<a href="#rid61">61-63</a>]. As a result, while diffusion-weighted MRI can facilitate lymph node detection, it is not sufficiently reliable for differentiating between benign and malignant lymph nodes [<a href="#rid64">64,65</a>]. Another potential use for diffusion-weighted MRI is in clarifying complete responses to neoadjuvant treatment, which may aid in the selection of patients for nonoperative management [<a href="#rid66">66</a>], but this is an ongoing area of investigation. (See  <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">"Neoadjuvant therapy for rectal adenocarcinoma", section on 'Tumor response assessment and follow-up'</a>.)</p><p class="headingAnchor" id="H4014244588"><span class="h3">Transrectal endoscopic ultrasound</span><span class="headingEndMark"> — </span>Consistent with consensus-based guidelines from the NCCN [<a href="#rid4">4</a>] and ESMO, MRI is generally preferred over TEUS for pretreatment staging of rectal cancer appropriate for resection unless MRI is contraindicated (eg, pacemaker). ESMO guidelines specifically state a preference for MRI over TEUS for intermediate and locoregionally advanced disease, but either TEUS or MRI is acceptable for a T1-2N0 tumor [<a href="#rid5">5</a>].</p><p>TEUS offers superior spatial resolution compared with standard CT and MRI techniques, which can provide more refined assessments of the depth of invasion for tumor staging. This superior resolution can be particularly useful in distinguishing T2 from early T3 tumors, which can be indistinguishable on MRI. (See <a class="local">'Magnetic resonance imaging'</a> above.)</p><p>Using TEUS, localized cancers involving only the mucosa and submucosa can usually be distinguished from T2 tumors, which penetrate the muscularis propria  (<a class="graphic graphic_diagnosticimage graphicRef50261" href="/z/d/graphic/50261.html" rel="external">image 9</a>), or T3 tumors, which extend transmurally into the perirectal fat  (<a class="graphic graphic_diagnosticimage graphicRef65054" href="/z/d/graphic/65054.html" rel="external">image 10</a>) [<a href="#rid67">67</a>]. The technique of TEUS is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2674.html" rel="external">"Endoscopic ultrasound for evaluating patients with rectal cancer"</a>.)</p><p>The sensitivity and specificity of TEUS for rectal cancer staging were addressed in a compilation of data from seven (2009 or later) systematic reviews by the AHRQ [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For identifying T1 disease  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>), the sensitivity was 88 percent (95% CI 85-90 percent), and the specificity was 98 percent (95% CI 98-99 percent). For identifying T2 disease, the sensitivity was 81 percent (95% CI 80-83 percent), and the specificity was 96 percent (95% CI 95-96 percent). For identifying T3 disease, the sensitivity was 96 percent (95% CI 95-97 percent), and the specificity was 91 percent (95% CI 90-92 percent). For identifying T4 disease, the sensitivity was 95 percent (95% CI 92-98 percent), and the specificity was 98 percent (95% CI 98-99 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For lymph node involvement (any involved versus all clear), the sensitivity was 73 percent (95% CI 71-76 percent), and the specificity was 76 percent (95% CI 74-78 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data were not available on the sensitivity and specificity for evaluating the status of the CRM. </p><p></p><p>The major limitations of TEUS include its field of view and its operator dependence. Because ultrasound cannot fully assess the regional nodal stations of rectal cancer, other modalities must be relied upon for comprehensive nodal staging [<a href="#rid68">68,69</a>]. There is also considerable interobserver variability and a significant learning curve associated with performing TEUS [<a href="#rid70">70</a>]. </p><p>Another challenge with TEUS is assessment of the CRM. For patients with anterior tumors, TEUS can assess the extent of tumor involvement of the mesorectal fascia, which predicts the distance of the tumor to the circumferential resection plane after surgery. However, for posterior or posterolateral tumors, the distance to the CRM cannot be estimated using TEUS because the neighboring structures that allow assessment of the CRM are lacking. In such cases, the distance to the CRM is best estimated using MRI. (See  <a class="medical medical_review" href="/z/d/html/2674.html" rel="external">"Endoscopic ultrasound for evaluating patients with rectal cancer", section on 'Circumferential resection margin'</a>.)</p><p>On the other hand, the ability to perform fine-needle aspiration (FNA) biopsy of suspicious perirectal lymph nodes is a potential advantage of TEUS over MRI. However, TEUS-guided FNA does not appear to improve rectal cancer staging in most patients, and it is not routinely performed [<a href="#rid71">71,72</a>]. One reason why FNA may not add significantly to TEUS alone is that perirectal lymph nodes may be too small to be visualized by TEUS unless they contain metastatic disease. Thus, biopsy would not be expected to improve sensitivity when compared with visual criteria alone. </p><p>The comparative performance of TEUS, MRI, and CT in local staging of rectal cancers is discussed in more detail below. (See <a class="local">'Comparative performance of MRI, TEUS, and CT'</a> below.)</p><p class="headingAnchor" id="H2877870689"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>CT scanning is a helpful modality for evaluating the presence of distant metastatic spread and for identifying tumor-related complications (eg, perforation, fistula formation), but it provides only limited local tumor and nodal staging information [<a href="#rid2">2,4</a>]. CT scans for rectal cancer staging are typically performed of the chest, abdomen, and pelvis using both oral and intravenous contrast (even if MRI of the pelvis is performed). (See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'Computed tomography scan'</a>.)</p><p>When examining locally advanced disease, CT determines local T stage with an accuracy of 79 to 94 percent; this falls to 52 to 74 percent when less advanced, smaller tumors are analyzed [<a href="#rid37">37,73-75</a>]. The sensitivity of CT for detecting perirectal nodal involvement depends on the size criteria used to define a node as potentially malignant, but it is generally inferior to that of TEUS and MRI. (See <a class="local">'Comparative performance of MRI, TEUS, and CT'</a> below.)</p><p class="headingAnchor" id="H623938"><span class="h3">Comparative performance of MRI, TEUS, and CT</span><span class="headingEndMark"> — </span>In general, transrectal endoscopic ultrasound (TEUS) and magnetic resonance imaging (MRI) are both useful for primary tumor staging. As noted above, MRI offers some advantages over TEUS: it permits a larger field of view and can visualize more proximal tumors, it tends to be less operator and technique dependent, it allows the study of stenotic tumors, it can characterize lymph nodes in a wider field of view, and as noted above, it can characterize perirectal lymph nodes on the basis of additional features beyond size. (See <a class="local">'Magnetic resonance imaging'</a> above and <a class="local">'Transrectal endoscopic ultrasound'</a> above.)</p><p>The diagnostic performance of these modalities has varied widely across studies and over time, likely due to a combination of differing populations, improving technology over time, variations in site-specific expertise, and different reference standards.</p><p>A year 2014 comparative effectiveness review by the AHRQ came to the following conclusions regarding initial staging with TEUS versus MRI versus computed tomography (CT), based upon an analysis of direct comparator studies [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The summary results are provided for preoperative tumor  (<a class="graphic graphic_table graphicRef116635" href="/z/d/graphic/116635.html" rel="external">table 4</a>) and nodal staging  (<a class="graphic graphic_table graphicRef116636" href="/z/d/graphic/116636.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TEUS is more accurate (ie, less likely to give an incorrect result; odds ratio 0.36, 95% CI 0.24-0.54), less likely to understage (odds ratio 0.63, 95% CI 0.44-0.89), and less likely to overstage rectal cancer than CT in the preoperative evaluation of T stage (13 studies, n = 595 patients, low strength of evidence).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no statistically significant difference between MRI and TEUS for preoperative rectal cancer tumor staging (six studies, n = 294 patients, low strength of evidence).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no statistically significant difference in accuracy across CT, MRI, or TEUS for preoperative nodal staging (18 studies, n = 845 patients, low strength of evidence).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While there is no statistically significant difference in accuracy between CT and MRI for rectal nodal staging, MRI is less likely to overstage (four studies, n = 123 patients, low strength of evidence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no comparison of MRI versus TEUS for assessment of the CRM.</p><p></p><p>The information obtained with TEUS and MRI may be complementary [<a href="#rid76">76</a>], and in some cases, both procedures may be needed, particularly for mid-stage tumors where there is uncertainty about T2 versus T3N0 disease or T2N0 versus N1 status.</p><p>As noted above, consensus-based guidelines from the NCCN [<a href="#rid4">4</a>] state a preference for MRI over TEUS for pretreatment staging of rectal cancer appropriate for resection unless MRI is contraindicated (eg, pacemaker). ESMO guidelines suggest a preference for MRI over TEUS for intermediate and locoregionally advanced disease, but either TEUS or MRI is acceptable for a T1-2N0 tumor [<a href="#rid5">5</a>]. Links to these and other society guidelines can be found elsewhere. (See <a class="local">'Society guideline links'</a> below.)</p><p>Regardless of the test that is chosen, the operating surgeon should ensure that the TEUS or MRI study is performed at an experienced center. A poor-quality MRI that is done in an inexperienced center without surface phased-array coils, without a high field strength magnet, or without a rectal protocol can result in mismanagement because of errors in preoperative staging. The same is true for TEUS, which is highly dependent on operator experience. </p><p class="headingAnchor" id="H778610809"><span class="h3">FDG-PET</span><span class="headingEndMark"> — </span>Positron emission tomography imaging using fluorodeoxyglucose (FDG-PET) has not been shown to add significant information to conventional imaging for initial locoregional staging of rectal cancer [<a href="#rid77">77,78</a>]. The utility of FDG-PET for preoperative staging for distant metastatic disease is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'Positron emission tomography scans'</a>.)</p><p class="headingAnchor" id="H1239129404"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115274.html" rel="external">"Society guideline links: Colorectal cancer"</a>.)</p><p class="headingAnchor" id="H40"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15412.html" rel="external">"Patient education: Colon and rectal cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/874.html" rel="external">"Patient education: Colon and rectal cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/860.html" rel="external">"Patient education: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29549318"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical resection is the cornerstone of curative therapy for patients with early stage, potentially resectable rectal cancer. Superficially invasive, small cancers may be effectively managed with limited surgery (such as local excision). However, most patients have more deeply invasive tumors that require low anterior resection or, in some cases, if located distally, abdominoperineal resection.</p><p></p><p class="bulletIndent1">The addition of adjuvant radiation therapy (RT) and chemotherapy can enhance both local control and cure rates in patients with either transmural invasion or positive perirectal lymph nodes. Such therapy is often administered preoperatively, given the more favorable long-term toxicity profile of this approach compared with postoperative treatment. Neoadjuvant RT or chemoradiotherapy is generally considered for T3/T4 and/or clinically node-positive T1/T2 tumors  (<a class="graphic graphic_table graphicRef111438" href="/z/d/graphic/111438.html" rel="external">table 1</a>), distal rectal tumors for which preoperative chemoradiotherapy may enhance the ability to preserve the anal sphincter, and tumors that appear to invade or are in close proximity to the mesorectal fascia on preoperative imaging because of the decreased likelihood of achieving a tumor-free circumferential resection margin (CRM) with upfront surgery. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determining the best operative approach and the selection of appropriate patients for initial RT or chemoradiotherapy rather than surgery are heavily dependent on accurate preoperative locoregional staging. Digital rectal examination (DRE), rigid proctoscopy, and preoperative imaging studies assist in determining the need for radical resection versus local excision, and whether the patient is a candidate for preoperative therapy. (See <a class="local">'History, physical examination, and endoscopy'</a> above and <a class="local">'Imaging evaluation'</a> above.)</p><p></p><p class="bulletIndent1">On DRE, fixation of the lesion to the anal sphincter, its relationship to the anorectal ring (the collection of muscles that makes up the sphincters), and fixation to both the rectal wall and pelvic wall muscles (levators) can be assessed. Rigid proctoscopy rather than flexible sigmoidoscopy can more accurately determine the distance between the distal tumor margin, the top of the anorectal ring, and the dentate line, as well as the orientation within the rectum (eg, anterior, posterior, left, and right). (See <a class="local">'Surgical anatomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients should undergo complete colonoscopy to the cecum to assess for a possible synchronous second primary colorectal cancer or other polyps. (See <a class="local">'Complete colonoscopy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An algorithm outlining our approach to imaging evaluation for individuals with newly diagnosed rectal cancer is provided, and described in detail in the sections below  (<a class="graphic graphic_algorithm graphicRef131308" href="/z/d/graphic/131308.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">Contrast-enhanced computed tomography (CT) scanning of the chest and abdomen is the most useful test for staging distant metastatic spread and for identifying tumor-related complications (eg, perforation, fistula formation). For some patients, particularly those with metastatic disease, CT alone may provide sufficient information about local staging to permit the selection of initial treatment. (See <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent1">However, in most cases, pelvic magnetic resonance imaging (MRI) or transrectal endoscopic ultrasound (TEUS) provides greater accuracy than CT for assessing the depth of tumor invasion, the presence of regional nodal metastases, and the likelihood of a positive CRM at the time of surgery, all of which may influence the choice of initial surgery versus RT or chemoradiotherapy. Either high-resolution MRI or TEUS should be performed to determine local T stage and assess for lymph node positivity for all patients with invasive rectal cancer, including those with pathologic T1 malignant polyps with favorable prognostic factors.</p><p></p><p class="bulletIndent1">Consistent with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), MRI is generally preferred over TEUS for pretreatment staging of rectal cancer appropriate for resection unless MRI is contraindicated (eg, pacemaker). ESMO guidelines specifically state a preference for MRI over TEUS for intermediate and locoregionally advanced disease, but either TEUS or MRI is acceptable for a T1-2N0 tumor. (See <a class="local">'Principles of rectal cancer staging by imaging'</a> above.)</p><p></p><p class="bulletIndent1">The information obtained with TEUS and MRI may be complementary, and in some cases, both procedures may be needed, particularly for mid-stage tumors where there is uncertainty about T2 versus T3N0 disease or T2N0 versus N1 status. (See <a class="local">'Magnetic resonance imaging'</a> above and <a class="local">'Transrectal endoscopic ultrasound'</a> above and <a class="local">'Comparative performance of MRI, TEUS, and CT'</a> above.)</p><p></p><p class="bulletIndent1">Regardless of the test that is chosen, the operating surgeon should ensure that the MRI or TEUS study is performed at an experienced center. A poor-quality MRI that is done in an inexperienced center without surface coils, without a high field strength magnet, or without a rectal protocol can result in mismanagement because of errors in preoperative staging. The same is true for TEUS, which is highly dependent on operator experience.</p><p></p><p class="headingAnchor" id="H2200811242"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Erik K Paulson, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731.</a></li><li><a class="nounderline abstract_t">McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing colorectal cancer surgery. J Natl Cancer Inst 2006; 98:1623.</a></li><li><a class="nounderline abstract_t">Schoellhammer HF, Gregorian AC, Sarkisyan GG, Petrie BA. How important is rigid proctosigmoidoscopy in localizing rectal cancer? Am J Surg 2008; 196:904.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv22.</a></li><li><a class="nounderline abstract_t">Cranley JP, Petras RE, Carey WD, et al. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? Gastroenterology 1986; 91:419.</a></li><li><a class="nounderline abstract_t">Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2000; 95:3053.</a></li><li><a class="nounderline abstract_t">You YN, Hardiman KM, Bafford A, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. Dis Colon Rectum 2020; 63:1191.</a></li><li><a class="nounderline abstract_t">Detering R, van Oostendorp SE, Meyer VM, et al. MRI cT1-2 rectal cancer staging accuracy: a population-based study. Br J Surg 2020; 107:1372.</a></li><li><a class="nounderline abstract_t">Rosén R, Nilsson E, Rahman M, Rönnow CF. Accuracy of MRI in early rectal cancer: national cohort study. Br J Surg 2022; 109:570.</a></li><li><a class="nounderline abstract_t">MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007; 243:132.</a></li><li><a class="nounderline abstract_t">MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333:779.</a></li><li><a class="nounderline abstract_t">Siddiqui MRS, Simillis C, Bhoday J, et al. A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours. Eur J Cancer 2018; 104:47.</a></li><li><a class="nounderline abstract_t">Merkel S, Mansmann U, Siassi M, et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16:298.</a></li><li><a class="nounderline abstract_t">Shin R, Jeong SY, Yoo HY, et al. Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer. Dis Colon Rectum 2012; 55:1220.</a></li><li><a class="nounderline abstract_t">Brown G, Radcliffe AG, Newcombe RG, et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003; 90:355.</a></li><li><a class="nounderline abstract_t">Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986; 2:996.</a></li><li><a class="nounderline abstract_t">Yoo HY, Shin R, Ha HK, et al. Does t3 subdivision correlate with nodal or distant metastasis in colorectal cancer? J Korean Soc Coloproctol 2012; 28:160.</a></li><li><a class="nounderline abstract_t">Evans J, Patel U, Brown G. Rectal cancer: primary staging and assessment after chemoradiotherapy. Semin Radiat Oncol 2011; 21:169.</a></li><li class="breakAll">Jessup JM, Goldberg RM, Asare EA, et al. Colon and Rectum. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.251.</li><li><a class="nounderline abstract_t">Alasari S, Lim D, Kim NK. Magnetic resonance imaging based rectal cancer classification: landmarks and technical standardization. World J Gastroenterol 2015; 21:423.</a></li><li><a class="nounderline abstract_t">Rosenberg R, Maak M, Schuster T, et al. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer? Dis Colon Rectum 2010; 53:761.</a></li><li><a class="nounderline abstract_t">Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246:693.</a></li><li><a class="nounderline abstract_t">Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638.</a></li><li><a class="nounderline abstract_t">Tepper JE. Reflections in rectosigmoid: retro-peritoneal vs. intra-peritoneal. Int J Radiat Oncol Biol Phys 1988; 14:1043.</a></li><li><a class="nounderline abstract_t">Raynaud L, Mege D, Zappa M, et al. Is magnetic resonance imaging useful for the management of patients with rectal villous adenoma? A study of 45 consecutive patients treated by transanal endoscopic microsurgery. Int J Colorectal Dis 2018; 33:1695.</a></li><li><a class="nounderline abstract_t">De Vargas Macciucca M, Casale A, Manganaro L, et al. Rectal villous tumours: MR features and correlation with TRUS in the preoperative evaluation. Eur J Radiol 2010; 73:329.</a></li><li class="breakAll">Pettaway CA, Srigley JR, Brookland RK, et al. Penis. In: AJCC Cancer Staging Manual, 8th ed, Amin MB, Edge SB, Greene FL, et al (Eds), Springer, New York 2017. p.701.</li><li><a class="nounderline abstract_t">Gabriel WB, Dukes C, Bussey HJ. Lymphatic spread in cancer of the rectum. Br J Surg 1935; 23:395.</a></li><li><a class="nounderline abstract_t">Moriya Y, Sugihara K, Akasu T, Fujita S. Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer. World J Surg 1997; 21:728.</a></li><li><a class="nounderline abstract_t">Ogura A, Konishi T, Beets GL, et al. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy. JAMA Surg 2019; 154:e192172.</a></li><li><a class="nounderline abstract_t">Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19:2212.</a></li><li><a class="nounderline abstract_t">Kobayashi H, Kikuchi A, Okazaki S, et al. Diagnostic performance of multidetector row computed tomography for assessment of lymph node metastasis in patients with distal rectal cancer. Ann Surg Oncol 2015; 22:203.</a></li><li><a class="nounderline abstract_t">Gualdi GF, Casciani E, Guadalaxara A, et al. Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: comparison with histologic findings. Dis Colon Rectum 2000; 43:338.</a></li><li><a class="nounderline abstract_t">Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003; 227:371.</a></li><li><a class="nounderline abstract_t">Blomqvist L, Machado M, Rubio C, et al. Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography. Eur Radiol 2000; 10:653.</a></li><li><a class="nounderline abstract_t">Kim NK, Kim MJ, Yun SH, et al. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. Dis Colon Rectum 1999; 42:770.</a></li><li><a class="nounderline abstract_t">Meyenberger C, Huch Böni RA, Bertschinger P, et al. Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer. Endoscopy 1995; 27:469.</a></li><li><a class="nounderline abstract_t">Dworák O. Number and size of lymph nodes and node metastases in rectal carcinomas. Surg Endosc 1989; 3:96.</a></li><li><a class="nounderline abstract_t">Hartman RI, Chang CY, Wo JY, et al. Optimizing adjuvant treatment decisions for stage t2 rectal cancer based on mesorectal node size: a decision analysis. Acad Radiol 2013; 20:79.</a></li><li><a class="nounderline abstract_t">Kim JH, Beets GL, Kim MJ, et al. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 2004; 52:78.</a></li><li><a class="nounderline abstract_t">Kim SH, Yoon JH, Lee Y. Added value of morphologic characteristics on diffusion-weighted images for characterizing lymph nodes in primary rectal cancer. Clin Imaging 2015; 39:1046.</a></li><li><a class="nounderline abstract_t">Gollub MJ, Arya S, Beets-Tan RG, et al. Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. Abdom Radiol (NY) 2018; 43:2893.</a></li><li><a class="nounderline abstract_t">Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994; 344:707.</a></li><li><a class="nounderline abstract_t">Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253:711.</a></li><li><a class="nounderline abstract_t">Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32:34.</a></li><li><a class="nounderline abstract_t">Hall NR, Finan PJ, al-Jaberi T, et al. Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence? Dis Colon Rectum 1998; 41:979.</a></li><li><a class="nounderline abstract_t">Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002; 89:327.</a></li><li><a class="nounderline abstract_t">Kaur H, Choi H, You YN, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics 2012; 32:389.</a></li><li><a class="nounderline abstract_t">Okizuka H, Sugimura K, Yoshizako T, et al. Rectal carcinoma: prospective comparison of conventional and gadopentetate dimeglumine enhanced fat-suppressed MR imaging. J Magn Reson Imaging 1996; 6:465.</a></li><li><a class="nounderline abstract_t">Vliegen RF, Beets GL, von Meyenfeldt MF, et al. Rectal cancer: MR imaging in local staging--is gadolinium-based contrast material helpful? Radiology 2005; 234:179.</a></li><li><a class="nounderline abstract_t">Jao SY, Yang BY, Weng HH, et al. Evaluation of gadolinium-enhanced T1-weighted magnetic resonance imaging in the preoperative assessment of local staging in rectal cancer. Colorectal Dis 2010; 12:1139.</a></li><li><a class="nounderline abstract_t">Akasu T, Iinuma G, Fujita T, et al. Thin-section MRI with a phased-array coil for preoperative evaluation of pelvic anatomy and tumor extent in patients with rectal cancer. AJR Am J Roentgenol 2005; 184:531.</a></li><li><a class="nounderline abstract_t">Tatli S, Mortele KJ, Breen EL, et al. Local staging of rectal cancer using combined pelvic phased-array and endorectal coil MRI. J Magn Reson Imaging 2006; 23:534.</a></li><li><a class="nounderline abstract_t">Kim SH, Lee JM, Lee MW, et al. Diagnostic accuracy of 3.0-Tesla rectal magnetic resonance imaging in preoperative local staging of primary rectal cancer. Invest Radiol 2008; 43:587.</a></li><li><a class="nounderline abstract_t">Maas M, Lambregts DM, Lahaye MJ, et al. T-staging of rectal cancer: accuracy of 3.0 Tesla MRI compared with 1.5 Tesla. Abdom Imaging 2012; 37:475.</a></li><li><a class="nounderline abstract_t">Smith NJ, Barbachano Y, Norman AR, et al. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 2008; 95:229.</a></li><li><a class="nounderline abstract_t">Kim TH, Woo S, Han S, et al. The Diagnostic Performance of MRI for Detection of Extramural Venous Invasion in Colorectal Cancer: A Systematic Review and Meta-Analysis of the Literature. AJR Am J Roentgenol 2019; 213:575.</a></li><li><a class="nounderline abstract_t">Siddiqui MRS, Simillis C, Hunter C, et al. A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases. Br J Cancer 2017; 116:1513.</a></li><li class="breakAll">Bruening W, Sullivan N, Paulson EC, et al. Imaging Tests for the Staging of Colorectal Cancer. 14-EHC046-EF, AHRQ Comparative Effectiveness Reviews; Agency for Healthcare Research and Quality, Rockville, MD 2014.</li><li><a class="nounderline abstract_t">Heijnen LA, Lambregts DM, Mondal D, et al. Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol 2013; 23:3354.</a></li><li><a class="nounderline abstract_t">Cho EY, Kim SH, Yoon JH, et al. Apparent diffusion coefficient for discriminating metastatic from non-metastatic lymph nodes in primary rectal cancer. Eur J Radiol 2013; 82:e662.</a></li><li><a class="nounderline abstract_t">Mir N, Sohaib SA, Collins D, Koh DM. Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis. J Med Imaging Radiat Oncol 2010; 54:358.</a></li><li><a class="nounderline abstract_t">Beets-Tan RG, Lambregts DM, Maas M, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2013; 23:2522.</a></li><li><a class="nounderline abstract_t">Jhaveri KS, Hosseini-Nik H. MRI of Rectal Cancer: An Overview and Update on Recent Advances. AJR Am J Roentgenol 2015; 205:W42.</a></li><li><a class="nounderline abstract_t">Ryan JE, Warrier SK, Lynch AC, Heriot AG. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis 2015; 17:849.</a></li><li><a class="nounderline abstract_t">Beynon J, Foy DM, Roe AM, et al. Endoluminal ultrasound in the assessment of local invasion in rectal cancer. Br J Surg 1986; 73:474.</a></li><li><a class="nounderline abstract_t">Solomon MJ, McLeod RS. Endoluminal transrectal ultrasonography: accuracy, reliability, and validity. Dis Colon Rectum 1993; 36:200.</a></li><li><a class="nounderline abstract_t">Puli SR, Reddy JB, Bechtold ML, et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol 2009; 16:1255.</a></li><li><a class="nounderline abstract_t">Rafaelsen SR, Sørensen T, Jakobsen A, et al. Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. Scand J Gastroenterol 2008; 43:440.</a></li><li><a class="nounderline abstract_t">Harewood GC, Wiersema MJ, Nelson H, et al. A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. Gastroenterology 2002; 123:24.</a></li><li><a class="nounderline abstract_t">Dumonceau JM, Polkowski M, Larghi A, et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2011; 43:897.</a></li><li><a class="nounderline abstract_t">Butch RJ, Stark DD, Wittenberg J, et al. Staging rectal cancer by MR and CT. AJR Am J Roentgenol 1986; 146:1155.</a></li><li><a class="nounderline abstract_t">Zerhouni EA, Rutter C, Hamilton SR, et al. CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology 1996; 200:443.</a></li><li><a class="nounderline abstract_t">Rifkin MD, Ehrlich SM, Marks G. Staging of rectal carcinoma: prospective comparison of endorectal US and CT. Radiology 1989; 170:319.</a></li><li><a class="nounderline abstract_t">Frasson M, Garcia-Granero E, Roda D, et al. Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. Cancer 2011; 117:3118.</a></li><li><a class="nounderline abstract_t">Grassetto G, Marzola MC, Minicozzi A, et al. F-18 FDG PET/CT in rectal carcinoma: where are we now? Clin Nucl Med 2011; 36:884.</a></li><li><a class="nounderline abstract_t">Raman SP, Chen Y, Fishman EK. Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET. J Gastrointest Oncol 2015; 6:172.</a></li></ol></div><div id="topicVersionRevision">Topic 2522 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496622" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Preoperative versus postoperative chemoradiotherapy for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105985" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Development of quality indicators for patients undergoing colorectal cancer surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095107" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : How important is rigid proctosigmoidoscopy in localizing rectal cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095107" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : How important is rigid proctosigmoidoscopy in localizing rectal cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881920" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3721127" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095318" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps. Practice Parameters Committee of the American College of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33216491" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32297326" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : MRI cT1-2 rectal cancer staging accuracy: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35277966" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Accuracy of MRI in early rectal cancer: national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984925" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30321773" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11686527" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The prognostic inhomogeneity in pT3 rectal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135579" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594673" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2430152" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22816060" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Does t3 subdivision correlate with nodal or distant metastasis in colorectal cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21645861" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rectal cancer: primary staging and assessment after chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21645861" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rectal cancer: primary staging and assessment after chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25593457" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Magnetic resonance imaging based rectal cancer classification: landmarks and technical standardization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20389210" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Does a rectal cancer of the upper third behave more like a colon or a rectal cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968156" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547717" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3283082" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reflections in rectosigmoid: retro-peritoneal vs. intra-peritoneal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30136172" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Is magnetic resonance imaging useful for the management of patients with rectal villous adenoma? A study of 45 consecutive patients treated by transanal endoscopic microsurgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19157738" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rectal villous tumours: MR features and correlation with TRUS in the preoperative evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19157738" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rectal villous tumours: MR features and correlation with TRUS in the preoperative evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lymphatic spread in cancer of the rectum</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9276704" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Importance of extended lymphadenectomy with lateral node dissection for advanced lower rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31268504" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271205" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25124470" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnostic performance of multidetector row computed tomography for assessment of lymph node metastasis in patients with distal rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10733115" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: comparison with histologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12732695" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795550" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10378601" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565885" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2672395" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Number and size of lymph nodes and node metastases in rectal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22947271" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Optimizing adjuvant treatment decisions for stage t2 rectal cancer based on mesorectal node size: a decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380850" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26278013" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Added value of morphologic characteristics on diffusion-weighted images for characterizing lymph nodes in primary rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29785540" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7915774" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Role of circumferential margin involvement in the local recurrence of rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475011" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24276776" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715152" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11872058" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22411939" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : MR imaging for preoperative evaluation of primary rectal cancer: practical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8724412" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Rectal carcinoma: prospective comparison of conventional and gadopentetate dimeglumine enhanced fat-suppressed MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15550372" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rectal cancer: MR imaging in local staging--is gadolinium-based contrast material helpful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19548900" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Evaluation of gadolinium-enhanced T1-weighted magnetic resonance imaging in the preoperative assessment of local staging in rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671375" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Thin-section MRI with a phased-array coil for preoperative evaluation of pelvic anatomy and tumor extent in patients with rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16523466" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Local staging of rectal cancer using combined pelvic phased-array and endorectal coil MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18648259" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diagnostic accuracy of 3.0-Tesla rectal magnetic resonance imaging in preoperative local staging of primary rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21674192" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : T-staging of rectal cancer: accuracy of 3.0 Tesla MRI compared with 1.5 Tesla.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932879" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31063424" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The Diagnostic Performance of MRI for Detection of Extramural Venous Invasion in Colorectal Cancer: A Systematic Review and Meta-Analysis of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28449006" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28449006" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821022" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24016824" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Apparent diffusion coefficient for discriminating metastatic from non-metastatic lymph nodes in primary rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20718916" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23743687" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26102418" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : MRI of Rectal Cancer: An Overview and Update on Recent Advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26260213" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3521785" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Endoluminal ultrasound in the assessment of local invasion in rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425429" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Endoluminal transrectal ultrasonography: accuracy, reliability, and validity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19219506" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18365909" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12105829" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21842456" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486559" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Staging rectal cancer by MR and CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8685340" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643135" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Staging of rectal carcinoma: prospective comparison of endorectal US and CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21264832" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21892038" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : F-18 FDG PET/CT in rectal carcinoma: where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830037" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
